Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
about
Molecular-targeted therapy for advanced gastric cancerMolecular-targeted first-line therapy for advanced gastric cancerChanging strategies for target therapy in gastric cancerTargeting receptor tyrosine kinases in gastric cancerGastric Cancer: New Drugs - New StrategiesTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesThe genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondA phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.Molecular targeting to treat gastric cancer.Pathogenetic mechanisms in gastric cancer.Recent advances in the HER2 targeted therapy of gastric cancerPreclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2Proteomic and metabolic prediction of response to therapy in gastric cancer.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Two dimensions in targeting HER2.Targeted therapy for esophagogastric cancers: a reviewTrastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancerTargeted therapies in gastric cancer and future perspectives.Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cellsMolecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesPrognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.Targeted therapies for metastatic esophagogastric cancerTargeted therapy for gastric cancer.Novel targeted agents for gastric cancer.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Targeting the human epidermal growth factor receptor 2 in esophageal cancer.Emerging tyrosine kinase inhibitors for esophageal cancer.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?HER2 therapies and gastric cancer: a step forward.The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.HER2 directed therapy for gastric/esophageal cancers.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.
P2860
Q24187006-E7D5966B-872B-4C64-B3B4-CA9A17FE669DQ26471049-476537AE-62DC-4725-93A3-073D594E295EQ26774513-FCC541EB-DBE0-46F0-BF84-9131A7DC2320Q27013050-435D40FE-A6F8-4988-B55D-801430FAAC0FQ27028079-98E16E96-8DC7-437E-9E19-56D99554AABDQ28077666-851B6587-BE63-4283-8053-846C3A1296CBQ28078788-15A93470-D2D9-46ED-80FA-80D7D7F4A6ABQ33556988-A880F44C-5B04-428A-AABA-BE7AF6BF53EAQ34326593-AE46EB3F-AF16-483E-83C5-5E446E02816BQ34326627-5032FFA0-7CAC-4DD5-898D-6A0805B44B5BQ34967104-AF17537D-E6F4-41C3-96B5-7AFFDAE19FF1Q35051651-E04AE34C-6E6F-43E5-AF06-4A8ED6892AE0Q35336183-058B7004-0E3E-44F5-AD0E-F606436B6C9CQ35863874-A9E66F5F-7005-43DF-9CC3-5FBE1C6A7E60Q35895143-F21A9101-71B7-4F4C-AAA4-2F3F265A3A2EQ36039645-E3AF7050-7217-475E-95C2-BC51CF752793Q36220464-0127F094-EB37-4B9F-B2CD-4EC406E57DDBQ36471685-BFD9CD4F-F4D7-4F59-A8D2-D28D52FF8CE3Q36645690-DBC4EB89-440E-4C8D-A31D-BB839492C023Q36750684-B778CDE0-C750-4291-9873-239BC85A2020Q36770478-334C9AC4-7C74-411C-8615-32ECC6BACD5CQ37241496-EE9C779A-75A6-4C4C-A687-4C29C0748FE3Q37468304-946C5AE6-FDE4-4960-B3F5-245AC583D93AQ37567784-2A751A7D-0BC2-44EE-8AA0-F5D67C7332DEQ37687713-497ED4BF-B0CB-45E1-AE86-6615F04FFA0DQ37724647-0E78143D-0039-44E8-9CE0-E4343F42EF8AQ37836513-9354D525-3047-4F94-BA9E-7EC91ECBA9D4Q38007119-02A9ACBE-CDA6-46EA-A295-DB055DD54F34Q38019657-17C20D4F-D54A-4A9E-B5EB-69B710E7F48EQ38074157-AE7595BB-CF1B-44A6-B94D-5241E63BE72CQ38097675-EC5F3FAD-CA94-4B52-A323-054F47A25255Q38110962-41ED768F-3991-4038-8601-465B935B2C97Q38139297-2041E3AA-2A4E-41B7-A433-3B88D226AD2CQ38151672-7BB272E4-1379-44C0-9BF2-981FD00EC519Q38177325-FD5F28E4-7DC5-4C9E-A7D8-D5B0CCA27514Q38199128-D0ED7D00-2FFE-455A-9986-EA915B53F755Q38210070-00CD5125-2E9E-4191-897F-1FBC34767E22Q38210387-9F1FCE2D-B0F1-47FF-86A3-632DD22CC64EQ38221886-A736F6A7-C867-4C66-9861-DADD85815B6EQ38222270-CCA49B47-8D95-458C-9AE9-A95CEDED40DE
P2860
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Southwest Oncology Group study ...... or metastatic gastric cancer.
@ast
Southwest Oncology Group study ...... or metastatic gastric cancer.
@en
type
label
Southwest Oncology Group study ...... or metastatic gastric cancer.
@ast
Southwest Oncology Group study ...... or metastatic gastric cancer.
@en
prefLabel
Southwest Oncology Group study ...... or metastatic gastric cancer.
@ast
Southwest Oncology Group study ...... or metastatic gastric cancer.
@en
P2093
P2860
P356
P1433
P1476
Southwest Oncology Group study ...... or metastatic gastric cancer.
@en
P2093
C D Blanke
C M Fenoglio-Preiser
K D Danenberg
S I Shibata
P2860
P304
P356
10.1093/ANNONC/MDR021
P577
2011-03-17T00:00:00Z